Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular Pathways: CDK4 Inhibitors for Cancer Therapy

3 May 2014

Abstract excerpt

Unrestrained growth is the hallmark of cancer, and disrupted cell-cycle regulation is, therefore, common. CDK4 is the key regulator of the G1-S transition. In complex with cyclin D, CDK4 phosphorylates retinoblastoma protein (Rb) and drives cell-cycle progression, a process inhibited by p16. The p16-CDK4-cyclin D-Rb is aberrant in the majority of cancers and is, thus, a logical target for anticancer therapy....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Cancer-related Molecular Pathways
Share to Chronic Lymphocytic Leukemia Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24795392
DOI: 10.1158/1078-0432.ccr-13-1551

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular Pathways: CDK4 Inhibitors for Cancer TherapyPMID 24795392Read ↗

Molecular Pathways: Targeting the Cyclin D–CDK4/6 Axis for Cancer TreatmentSemantic proximity Read ↗

Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 – 2014)Semantic proximity Read ↗

Cell cycle regulation and anticancer drug discoverySemantic proximity Read ↗

Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016)Semantic proximity Read ↗

Targeting CDK4/6 in patients with cancerSemantic proximity Read ↗

Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer TreatmentSemantic proximity Read ↗

The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in MelanomaSemantic proximity Read ↗

Inhibitors of Cell Cycle Kinases: Recent Advances and Future Prospects as Cancer TherapeuticsSemantic proximity Read ↗

CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer AgentsSemantic proximity Read ↗

Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An UpdateSemantic proximity Read ↗

Mechanistic Roles of Transcriptional Cyclin-Dependent Kinases in Oncogenesis: Implications for Cancer TherapySemantic proximity Read ↗

Recent advances with cyclin-dependent kinase inhibitors: therapeutic agents for breast cancer and their role in immuno-oncologySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.